GSK Funds a New Startup with Immunometabolic Focus
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disea…
EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessin…
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Citryll announced its Board has been strengthened with two industry veterans with impressive track-records.
Who is Paul-Peter Tak?
Paul Peter Tak, MD, PhD served as Professor of Medicine and C…
Candel Therapeutics Appoints Pharma Veteran And Immunologist Paul-Peter Tak, M.D, PH.D. as CEO
Candel Therapeutics appoints Pharma veteran and immunologist Paul-Peter Tak, M.D., PH.D., as Chief Executive Officer, expands leadership team with Chief Financial Officer, Chief Business Officer and…
Pioneering Gut Science, Kintai Therapeutics Is Bringing a New Small Molecule Modality to Fruition
What if the gut, widely regarded as the body’s second brain, could offer a much more impactful means to effect broad systemic pharmacological actions of orally administered drugs based on the conflu…
Ten Pillars of Success for Building a Biotech Company (or any Innovative Organization)
First year reflections: Ten Pillars of Success for Building a Biotech Company
A year has passed since I joined Candel Therapeutics as its CEO!
What did I find when I joined?
A late cl…
